Publications by authors named "Geetha Shankar"

Claim this Profile
I
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, Martin Reck, Christian A Thomas, Geetha Shankar

J Thorac Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in mutated non-small cell lung cancer with , or comutations: subgroup results from the phase III IMpower150 trial.
Howard Jack West, Mark McCleland, Federico Cappuzzo, Martin Reck, Tony Sk Mok, Geetha Shankar

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Mark A Socinski, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Geetha Shankar

J Thorac Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, Thomas Wehler, Francisco Orlandi, Naoyuki Nogami, Carlo Barone, Geetha Shankar

J Clin Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.
Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland

Expert Rev Respir Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Geetha Shankar

Lancet Respir Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Marcin Kowanetz, Wei Zou, Scott N Gettinger, Hartmut Koeppen, Mark Kockx, Geetha Shankar

Proc Natl Acad Sci U S A· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Stephen Leong, Rebecca A Moss, Daniel W Bowles, Joseph A Ware, Jing Zhou, Geetha Shankar

Oncologist· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Jean-Charles Soria, Alex A Adjei, Rastilav Bahleda, Benjamin Besse, Charles Ferte, Geetha Shankar

Eur J Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Solange Peters, Scott Gettinger, Melissa L Johnson, Pasi A Jänne, Marina C Garassino, Geetha Shankar

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Mohamed A Ibrahim, Henry W B Johnson, Joon Won Jeong, Gary L Lewis, Xian Shi, Geetha Shankar

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate.
Hana Dolezalova, Geetha Shankar, Mei-Chuan Huang, Daniel D Bikle, Edward J Goetzl

J Cell Biochem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate.
Markus Graeler, Geetha Shankar, Edward J Goetzl

J Immunol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysophospholipid mediators of immunity and neoplasia.
Mei Chuan Huang, Markus Graeler, Geetha Shankar, Juliet Spencer, Edward J Goetzl

Biochim Biophys Acta· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer.
Edward J Goetzl, Markus Graeler, Mei-Chuan Huang, Geetha Shankar

ScientificWorldJournal· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis